Hollow-Fiber Bioreactor Gas Transfer Patents: Who Files, Where the Gaps Sit
Five assignees hold 60.7% of the field. 108 of 178 records in scope sit with the top five filers, and the ranked leader alone accounts for 38 records — this is a concentrated space, not an open one. Filings rose to a peak of 22 in 2017 and have not matched that level since. The 2021-to-2024 window shows a 67% drop, from 6 records to 2 — the clearest complete-year comparison the data supports. Treat 2025 and 2026 counts as undercounted rather than as confirmation the field is shrinking further.
- 1UNIVERCELLS SA38
- 2PLURI BIOTECH LTD34
- 3THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK15
- 4THE UNIV OF NORTH CAROLINA AT CHAPEL HILL12
- 5ADELLO BIOLOGICS LLC9
See the full hollow-fiber bioreactor gas transfer analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in hollow-fiber bioreactor gas transfer?
One assignee leads with 38 of the 178 records in scope, more than four times the count held by the fifth-ranked filer at 9. The top five assignees combined hold 108 records, or 60.7% of all records in scope, and the top ten hold 77.5%. That leaves a long tail across the remaining 37 ranked companies, most holding only a handful of records each.
Is patent filing in this space growing or shrinking?
Filing peaked in 2017 at 22 records and has trended down since, with the clearest complete-year comparison showing a 67% drop from 6 records in 2021 to 2 in 2024. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in any dataset pulled today are undercounts and should not be read as confirming a further decline.
What technology areas do these patents actually cover?
Nearly all records, 95.5% of the 178 in scope, carry a C12M bioreactor-and-enzyme-apparatus classification, making it the near-universal category for this search. A substantial minority also touch C12N microorganism and genetic-engineering claims (34.8%), with smaller shares in implant, agrochemical, medicinal-preparation, body-fluid-device and separation-process classifications. Because records can carry multiple IPC codes, these shares add up to well over 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Hollow-Fiber Bioreactor Gas Transfer covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.